Dynamic Advisor Solutions LLC Grows Holdings in Abbott Laboratories $ABT

Key Points

• Dynamic Advisor Solutions LLC increased its stake in Abbott Laboratories by 53.8% during Q2, now holding 38,392 shares valued at approximately $5.22 million.
• Abbott Laboratories reported a quarterly revenue of $11.14 billion, surpassing estimates, with an EPS of $1.26 aligning with analysts' expectations.
• Analysts' ratings show a favorable outlook for Abbott Laboratories, with two analysts giving a Strong Buy rating and a consensus price target of $144.47.

Dynamic Advisor Solutions LLC boosted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 53.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,392 shares of the healthcare product maker's stock after purchasing an additional 13,437 shares during the period. Dynamic Advisor Solutions LLC's holdings in Abbott Laboratories were worth $5,222,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Hughes Financial Services LLC bought a new stake in Abbott Laboratories in the 1st quarter worth approximately $27,000. Abound Financial LLC bought a new stake in Abbott Laboratories in the 1st quarter worth approximately $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $30,000. Wormser Freres Gestion bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $32,000. Finally, JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $32,000. Institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Mizuho lifted their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research note on Wednesday, July 16th. Royal Bank Of Canada upped their price target on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a report on Friday, July 18th. Leerink Partners initiated coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target on the stock. Finally, Evercore ISI upped their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $145.22.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Trading Up 1.2%

ABT stock traded up $1.65 during trading on Friday, reaching $136.22. 11,531,874 shares of the stock were exchanged, compared to its average volume of 4,828,819. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The business has a 50 day moving average price of $130.47 and a 200-day moving average price of $131.14. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The firm has a market capitalization of $237.09 billion, a price-to-earnings ratio of 17.07, a P/E/G ratio of 2.58 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. Abbott Laboratories's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.